Scientific Program
07:30
Registration
08:50
Congress Opening & Welcome
Alessandro Isidori, Italy -Congress Chair
09:00-10:30
AML. First Debate: Leukemia Biology
Chair: Antonio Curti, Italy
09:00-09:30
Inflammation and T-cell dysfunction in acute myeloid leukaemia
Sergio Rutella
Nottingham Trent University, UK
09:30-10:00
Re peculiar characteristics of the leukemia cell impact on immune evasion and on the differentiation of immunogenic/immunoregulatory susbets (title tbc)
Luca Vago
San Raffaele Scientific Institute, Milan, Italy
10:00-10:30
Re role of intrinsic and extrinsic factors in the MDS and AML (title tbc)
Shahram Kordasti
King's College Hospital London, UK
10:30-11:00
Coffee Break, Exhibition & Poster Viewing
11:00-12:30
Second Debate: What to do for intermediate-risk AML in first CR
Chair: Adolfo de la Fuente Burguera, Spain
11:00-11:30
Maintenance
Giuseppe Visani
Marche Nord Hospital - Pesaro, Italy
11:30-12:00
Front-line allo-transplant candidate AML patients
Mar Tormo
Valencia University Clinic Hospital, Spain
12:00-12:30
How to intergrate targeted therapies in Intermediate-risk AML
Adolfo de la Fuente Burguera
MD Anderson Cancer Center Madrid, Spain
12:30-13:30
Lunch Break, Exhibition & Poster Viewing
13:30-15:00
Third Debate: High-risk AML
Chair: Thomas Cluzeau, France
13:30-14:00
Definition of High-risk AML based on ICC and WHO
Madlen Jentzsch
University Hospital Leipzig, Germany
14:00-14:30
Therapeutical strategies in high-risk AML eligible to intensive chemotherapy
Thomas Cluzeau
Centre Hospitalier Universitaire de Nice (CHU de Nice), France
14:30-15:00
Therapeutical strategies in high-risk AML not eligible to intensive chemotherapy
Jean-Baptiste Micol
Gustave Roussy Hospital, France
15:00-15:30
Coffee Break, Exhibition & Poster Viewing
15:30-16:30
Fourth Debate: Allogeneic stem cell transplantation in acute leukemia
Chair: Yngvar Floisand, Norway
15:30-16:00
Graft engineering
Jürgen Kuball
University Medical Center Utrecht, Netherlands
16:00-16:30
Immunotherapeutic strategies after allogeneic stem cell transplantation
Alexandros Spyridonidis
University of Patras, Greece
16:30-17:00
Drug-based maintenance strategies after allogeneic stem cell transplantation
Yngvar Floisand
University of Oslo, Norway
17:00-18:30
Fifth Debate: The challenge of resistance and relapse after Anti-bcl2 based therapy
Chair: Klaus Metzeler, Germany
17:00-17:30
Mechanisms of resistance to Anti-bcl2 in AML
Klaus Metzeler
University of Leipzig, Germany
17:30-18:00
Predicting clinical sensitivity to Anti-bcl2 – functional or genetic analyses?
Simon Renders
University Hospital Heidelberg, Germany
18:00-18:30
What can we offer our patients progressing after Anti-bcl2/HMAs??
Christoph Schliemann
University of Münster, Germany
08:00
Registration
09:00-10:30
CLL. Sixth Debate: Fixed duration versus continuous therapy
Chair: Paolo Sportoletti, Italy
09:00-09:30
Fixed duration therapy
Lydia Scarfò
San Raffaele Scientific Institute, Italy
09:30-10:00
Continuous therapy
Andrea Visentin
University of Padua, Italy
10:00-10:30
Hot to sequence treatment in CLL
Paolo Sportoletti
University of Perugia, Italy
10:30-11:00
Coffee Break, Exhibition & Poster Viewing
11:00-12:30
ALL. Seventh Debate: Novel treatments in ALL
Chair: Alessandro Isidori, Itay on behalf of Oliver Ottmann, UK
11:00-11:30
Stem cell transplantation and CAR T-cell in ALL: where do we stand and what is the future?
Eolia Brissot
Saint-Antoine Hospital, Sorbonne University, France
11:30-12:00
Philadelphia positive ALL: evolving strategies
Fabian Lang
Goethe University Hospital, Germany
12:00-12:30
Immunotherapy for Ph-negative ALL
Sabina Chiaretti
Sapienza University of Rome, Italy
12:30-13:30
Lunch Break, Exhibition & Poster Viewing
13:30
LECTURE
How I treat CML in 2023
Giuseppe Saglio
University of Turin, Italy
14:00-15:15
Best Abstracts Session
Chair: Alessandro Isidori, Italy - Congress chair
| 14:00-14:15 | Diarylheptanoids 7-(3,4-dihydroxyphenyl)-5- hydroxy-1-phenyl-(1E)- 1-heptene from Curcuma comosa Roxb. inhibits nucleophosmin localization and induces apoptosis in KG-1a leukemic stem cells Natsima Viriyaadhammaa, Thailand |
| 14:15-14:30 | Promising Results of Treatment with Hybrid Protocol CLAG-M in Patients with Mixed Phenotype Acute Leukemia; Polish Adult Leukemia Group experience Magdalena Karasek, Poland |
| 14:30-14:45 | Prognostic and Predictive role of Complex Karyotype in Patients with Chronic Lymphocytic Leukemia Treated with Venetoclax-based Regimens Andrea Serafin, Italy |
| 14:45-15:00 | NUP214 Fusion Genes in T-cell Acute Lymphoblastic Leukemias Marta Brunetti, Norway |
| 15:00-15:30 | Defining immune pathways involved in the depletion of B-cell precursor acute lymphoblastic leukemia-initiating cells following early-life cytomegalovirus (CMV) infection in mice Ali Farrokhi, Canada |
15:15
Best Abstract Award Announcement
15:20
Congress Closing Remarks
Alessandro Isidori, Italy - Congress Chair
